Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 3).
D000293:Adolescent; D000856:Anorexia Nervosa / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D003863:Depression / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003907:Dexamethasone; D003937:Diagnosis, Differential; D004775:Enuresis / Q000628:therapy; D005260:Female; D006801:Humans; D006963:Hyperphagia / Q000209:etiology / Q000523:psychology; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D012561:Schizophrenia, Childhood / Q000175:diagnosis / Q000188:drug therapy*; D012737:Sex Factors
D000929:Antidepressive Agents, Tricyclic; D003907:Dexamethasone; D008094:Lithium